이름
이소영
(Lee, Soyoung)
전공
임상약학
연락처
연구실
임상약리학 연구실
최종학력
2012.03~2016.02 이화여자대학교 약학대학 (약학사) 2016.09~2021.02 서울대학교 의과대학 (의학박사)
경력
2016. 2. ~ 2024. 2. 서울대학교병원 임상약리학과 2021. 3. ~ 2023. 9. 서울대학교 의학연구원 (선임연구원) 2023. 10. ~ 2024. 2. 서울대학교 BK 맞춤형헬스케어 사업단 (BK조교수) 2024. 3. ~ 충남대학교 약학대학 (조교수)
관심연구분야
Personalized Pharmacotherapy Model Informed Drug Development
연구논문
1. Khwarg, J., Lee, S., Jang, I. J., Kang, W. H., Lee, H. J., Kim, K. Y., ... & Oh, J. (2024). Pharmacokinetic Comparison
Between a Fixed-Dose Combination of Atorvastatin/Omega-3-Acid Ethyl Esters and the Corresponding Loose
Combination in Healthy Korean Male Subjects. Drug Design, Development and Therapy, 395-406.
2. Khwarg, J., Chung, W. K., Lee, S., Yang, E., Ryu, C., Lee, D. Y., Lee, M., Jang, I. J., Yu, K. S., Lee, S. (2023).
Evaluation of Food Effect on the Pharmacokinetics of Velufenacin, a New Muscarinic Receptor Antagonist, in
Healthy Subjects. Clinical Pharmacology in Drug Development.
3. Kim, H. C., Yang, E., Lee, S., Oh, J., Lee, M., Lee, C., Ha, K., Lee, W., Jang, I. J., Yu, K. S. (2023). Effects of food and
ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean,
Caucasian, and Chinese male subjects. Investigational New Drugs.
4. Lee, S., Kim, H. C., Jang, Y., Lee, H. S., Ahn, S. J., Lee, S. T., Jung, K. H., Park, K. I., Jung, K. Y., Oh, J., Lee, S., Yu,
K. S., Jang, I. J., Lee, S., Chu, K., Lee, S. K. (2023). Topiramate dosage optimization for effective antiseizure
management via population pharmacokinetic modeling. Annals of Clinical and Translational Neurology.
5. Hwang, S., Lee, S., Yoon, J., Chung, J. Y. (2023). Population Pharmacokinetic− Pharmacodynamic Modeling of
Carvedilol to Evaluate the Effect of Cytochrome P450 2D6 Genotype on the Heart Rate Reduction. Journal of
Korean Medical Science, 38(22).
6. Lee, S., Hong, K. T., Jang, I. J., Yu, K. S., Kang, H. J., Oh, J. (2023). Semimechanistic pharmacokinetic–
pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy. CPT: Pharmacometrics &
Systems Pharmacology, 12(9), 1319-1334.
7. Lee, H., Chung, J. Y., Yu, K. S., Park, S. J., Lee, S. (2023). Pharmacokinetic Comparison Between a Fixed‐Dose
Combination of Empagliflozin L‐Proline/Metformin and Empagliflozin/Metformin in Healthy Korean
Subjects. Clinical Pharmacology in Drug Development.
8. Lee, S., Hwang, S. K., Nam, H. S., Cho, J. S., Chung, J. Y. (2022). Population Pharmacokinetic Model of AST-001,
L-Isomer of Serine, Combining Endogenous Production and Exogenous Administration in Healthy Subjects.
Frontiers in Pharmacology.
9. Hwang, S., Lee, S., Kim, E., Hwang, I., Cho, J. Y., Chung, J. Y., Jang, I. J., Oh, J. (2022). The pharmacokinetic,
safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjects.
Clinical and Translational Science.
10. Lee, S., Hong, K. T., Moon, S. J., Choi, J. Y., Hong, C. R., Shin, H. Y., Oh, J. & Kang, H. J. (2021). Pharmacokinetic
and pharmacodynamic characteristics of tripegfilgrastim, a pegylated G‐CSF, in pediatric patients with solid
tumors. Clinical Pharmacology & Therapeutics.
11. Huh, K. Y., Kim, E., Lee, S., Yoo, H., Yoon, S., Yu, K. S., & Chung, J. Y. (2021). Current bioequivalence study
designs in Republic of Korea: a comprehensive analysis of bioequivalence study reports between 2013 and
2019. Frontiers in pharmacology, 12.
12. Lee, S., Lee, Y., Kim, A. H., Yoon, S., Lee, J., Ji, S. C., Yoon, S. H., Lee, S., Yu, K. S., Jang, I. J., & Cho, J. Y. (2020).
Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects. Drug
Metabolism and Pharmacokinetics.
13. Lee, S., Kim, A. H., Yoon, S., Lee, J., Lee, Y., Ji, S. C., Yoon, S. H., Lee, S., Yu, K. S., Jang, I. J., & Cho, J. Y. (2020).
The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and
CYP3A inhibitors in healthy subjects. Drug Metabolism and Pharmacokinetics.
14. Jung, J., Lee, S., Oh, J., Lee, S., Jang, I. J., Lee, D., & Yu, K. S. (2021). Pharmacokinetic comparison between a
fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose
combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects.
Translational and Clinical Pharmacology, 29(1), 53.
15. Yoon, D. Y., Lee, S., Ban, M. S., Jang, I. J., Lee S. (2020). Pharmacogenomic information from CPIC and DPWG
guidelines and its application on drug labels. Translational and Clinical Pharmacology, 28(4), 189-198.
16. Yang, E., Lee, S., Lee, H., Hwang, I., Jang, I. J., Yu, K. S., & Lee, S. (2019). Pharmacokinetic comparison between
fixed-dose combination of fimasartan/amlodipine 60/10 mg and the corresponding loose combination through
partial replicated crossover study in healthy subjects. Translational and Clinical Pharmacology, 27(4), 134-140.
17. Lee, S., Yoon, S., Chung, H., Ji, S. C., Yoon, S. H., Yu, K. S., & Chung, J. Y. (2019). Pharmacokinetics of
Ursodeoxycholic Acid in Elderly Volunteers Compared With Younger Adults in a Korean Population. The Journal
of Clinical Pharmacology, 59(8), 1085-1092.
18. Rhee, S., Lee, H. A., Lee, S., Kim, E., Jeon, I., Song, I. S., & Kyung-Sang, Y. (2018). Physiologically Based
Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug–
Drug Interaction Potentials. Pharmaceutical Research, 35(12), 1-10.
19. Lee, S., Kim, Y., Lee, J. J. S., Im, G., Cho, J. Y., Chung, J. Y., & Yoon, S. (2018). A pharmacokinetic drug-drug
interaction study between pregabalin and tramadol in healthy volunteers. European journal of clinical
pharmacology, 74(12), 1605-1613.
20. Lee, S., Nam, K. Y., Oh, J., Lee, S., Cho, S. M., Choi, Y. W., & Hong, J. H. (2018). Evaluation of the effects of food
on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of
immediate-release tablet. Drug design, development and therapy, 12, 1413.